Serum ceruloplasmin level as a predictor for the progression of diabetic nephropathy in korean men with type 2 diabetes mellitus

Diabetes and Metabolism Journal

Volumn 39, Issue 3, 2015, Pages 230-239

  Lee, Min Jung ^a   Jung, Chang Hee ^a   Kang, Yu Mi ^a   Jang, Jung Eun ^a   Leem, Jaechan ^a   Park, Joong Yeol ^a   Lee, Woo Je ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Ceruloplasmin; Diabetic nephropathies; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CERULOPLASMIN; CREATININE; HEMOGLOBIN A1C; URIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENCE; KOREAN (PEOPLE); LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREVALENCE; PROTEIN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 84932642309     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2015.39.3.230     Document Type: Article

References (29)

1. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-8.
2. Gordois A, Scuffham P, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004;18:18-26.
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9.
4. Harris ZL. Aceruloplasminemia. J Neurol Sci 2003;207:108-9.
5. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006;187:238-50.
6. Cunningham J, Leffell M, Mearkle P, Harmatz P. Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication. Metabolism 1995;44:996-9.
7. Daimon M, Susa S, Yamatani K, Manaka H, Hama K, Kimura M, Ohnuma H, Kato T. Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Diabetes Care 1998; 21:1525-8.
8. Memisogullari R, Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with type 2 diabetes mellitus. J Diabetes Complications 2004;18:193-7.
9. Jung CH, Lee WJ, Yu JH, Hwang JY, Shin MS, Koh EH, Kim MS, Park JY. Elevated serum ceruloplasmin levels are associated with albuminuria in Korean men with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;94:e3-7.
10. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW; American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004;27 Suppl 1:S79-83.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.
12. Hellemons ME, Kerschbaum J, Bakker SJ, Neuwirt H, Mayer B, Mayer G, de Zeeuw D, Lambers Heerspink HJ, Rudnicki M. Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review. Diabet Med 2012;29:567-77.
13. Ujihara N, Sakka Y, Takeda M, Hirayama M, Ishii A, Tomonaga O, Babazono T, Takahashi C, Yamashita K, Iwamoto Y. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract 2002;58: 109-14.
14. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013;124:139-52.
15. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 2003;42:53-61.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-53.
17. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65:2309-20.
18. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009;169:342-50.
19. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-65.
20. Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Semin Nephrol 2011;31:459-65.
21. Zhang Y, Yamamoto T, Hisatome I, Li Y, Cheng W, Sun N, Cai B, Huang T, Zhu Y, Li Z, Jing X, Zhou R, Cheng J. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic beta cells. Mol Cell Endocrinol 2013;375:89-96.
22. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996;49: 1774-7.
23. Sontakke AN, More U. Changes in serum ceruloplasmin levels with commonly used methods of contraception. Indian J Clin Biochem 2004;19:102-4.
24. Kedziora-Kornatowska K, Kornatowski T, Bartosz G, Pawluk H, Czuczejko J, Kedziora J, Szadujkis-Szadurski L. Production of nitric oxide, lipid peroxidation and oxidase activity of ceruloplasmin in blood of elderly patients with primary hypertension. Effects of perindopril treatment. Aging Clin Exp Res 2006;18 :1-6.
25. Milne DB, Johnson PE. Assessment of copper status: effect of age and gender on reference ranges in healthy adults. Clin Chem 1993;39:883-7.
26. Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, Shimotomai T, Koshimura J, Fujita H, Kakei M, Ito S. Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 2004;27:1176-81.
27. Williams ME. Diabetic nephropathy: the proteinuria hypothesis. Am J Nephrol 2005;25:77-94.
28. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-7.
29. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832-9.